Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quoin Pharmaceuticals Ltd. (QNRX)

Quoin Pharmaceuticals receives EMA orphan drug designation for QRX003 in Peeling Skin Syndrome

Neutral Impact 3 of 5 legal/regulatory Written later

Quoin Pharmaceuticals said on October 14, 2026 that the European Medicines Agency granted Orphan Drug Designation to its lead product candidate QRX003 for treating Peeling Skin Syndrome. If QRX003 is approved for marketing by the EMA, the company would receive 10 years of market exclusivity in Europe for similar medicines for this indication, and the company plans to start the first-ever formal clinical study for the condition before year end.

Key points

  • EMA granted Orphan Drug Designation to QRX003 for Peeling Skin Syndrome, announced October 14, 2026
  • Designation brings scientific advice on study protocols, various fee reductions and access to EU grants
  • If approved by the EMA, QRX003 would receive 10 years of market exclusivity in Europe for this indication
  • The company intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end

The filing

CompanyQuoin Pharmaceuticals Ltd. (QNRX)
Form8-K, current report
Filed with the SECOct 14, 2026, 6:35 AM ET
Accession number0001104659-26-115709

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.